Atorvastatin exerts a rapid, direct effect on GTP- cyclohydrolase I expression in human arteries leading to a striking improvement of vascular redox state

Atorvastatin protects the integrity of adherens junctions in endothelial cells by inhibiting VE-cadherin tyrosine phosphorylation

Soluble Lectin-like Oxidized LDL Receptor-1 and High Sensitivity Troponin T when measured in combination, improved the accuracy of ACS diagnosis in emergency rooms

REACH Registry: 22% excess in long-term adverse clinical events in patients with established atherosclerosis due to lack of use of evidence-based secondary prevention therapies at 1 year

Levels of class A macrophage scavenger receptor SR-A increase in unstable atherosclerotic plaque and peripheral blood mononuclear cells in ACS patients

Septolateral LV mechanical dyssynchrony is a strong and independent predictor of long term survival in systolic heart failure patients independent of QRS duration

Major life events in the year prior to acute myocardial infarction are associated with worse 1-year outcomes

In chronic heart failure patients, therapy guided by NT-proBNP leads to greater improvements in quality of life, than standard management therapy

Elevated oxidative stress in patients with normal left ventricular ejection fraction independently correlates with left ventricular mass index

Hemodynamic correction through ventricular assist device implantation modifies the altered bone turnover, in patients with advances heart failure

Elevated circulating levels of sCD93 are associated with clinical outcomes in patients with acute myocardial infaction

Addition of very low dose rivaroxaban to dual antiplatelet therapy in patients hospitalized with a recent ACS significantly reduced mortality, and ischemic events for a median of 1.1 years with a significant increase in non–CABG-related TIMI major bleeding and ICH.

Addition of vorapaxar to dual antiplatelet therapy in patients hospitalized with a recent ACS does not significantly reduce ischemic events, but increases bleeding events.

Use of bivalirudin alone results in similar ischemic events and less bleeding compared with unfractionated heparin/abciximab, in patients with NSTEMI

Administration of intracoronary abciximab compared with intravenous abciximab failed to improve composite clinical outcomes or reduce infarct size, in STEMI patients undergoing primary PCI

Extended duration of VTE prophylaxis with oral apixaban is not superior to in-hospital subcutaneous enoxaparin in patients admitted with acute medical illness and is associated with an increased risk of bleeding